Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Income from Continuing Operations (2020 - 2025)

Journey Medical's Income from Continuing Operations history spans 6 years, with the latest figure at 1247000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 178.82% year-over-year to 1247000.0, compared with a TTM value of 11431000.0 through Dec 2025, up 21.76%, and an annual FY2025 reading of 11431000.0, up 22.08% over the prior year.
  • Income from Continuing Operations for Q4 2025 was 1247000.0 at Journey Medical, up from 2315000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 16789000.0 in Q3 2023, with the low at 21751000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 5175850.0, with a median of 3934500.0 recorded in 2025.
  • Year-over-year, Income from Continuing Operations plummeted 36810.34% in 2021 and then skyrocketed 266.56% in 2023.
  • Tracing DERM's Income from Continuing Operations over 5 years: stood at 21751000.0 in 2021, then skyrocketed by 51.07% to 10642000.0 in 2022, then soared by 79.86% to 2143000.0 in 2023, then soared by 173.82% to 1582000.0 in 2024, then tumbled by 178.82% to 1247000.0 in 2025.
  • Per Business Quant, the three most recent readings for DERM's Income from Continuing Operations are 1247000.0 (Q4 2025), 2315000.0 (Q3 2025), and 3796000.0 (Q2 2025).